Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRINT: Dapagliflozin in Anthracycline-related Cardiotoxicity
NCT07070765Recruiting
- Sponsor
- University of Aberdeen
- Start
- Dec 2025
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of dapagliflozin in Cardiotoxicity (2 arms), sponsored by University of Aberdeen. Primary endpoint: Cardiac energetics at 22 weeks. Started Dec 2025; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT07070765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07070765.